Scientific deep-dive
What Is GLP-3? There Is No Such Hormone — Here's What People Mean
GLP-3 is not a real hormone, receptor, or approved drug. It is a nickname for retatrutide, an investigational Eli Lilly triple agonist of the GLP-1, GIP, and glucagon receptors; the 3 counts receptors. Products sold online as GLP-3 are unapproved retatrutide.
There is no such thing as GLP-3. No hormone, no receptor, and no approved drug by that name — a full-label search of FDA's DailyMed for “GLP-3” on August 19, 2026 returned zero results. What people mean when they say it is retatrutide, an investigational Eli Lilly molecule that activates three receptors at once. The “3” counts receptors, not generations of a hormone. That distinction matters more than it sounds, because the term has become the label under which unapproved retatrutide is sold online as “GLP-3 peptide,” “GLP-3 RT,” and “GLP-3 R.” The same confusion is starting around cagrilintide and petrelintide, which are amylin analogs rather than GLP-1s at all.
The short answer
| Term | Is it real? | What it is |
|---|---|---|
| GLP-1 | Yes | Glucagon-like peptide-1. The hormone behind semaglutide (Wegovy, Ozempic) and part of tirzepatide. |
| GLP-2 | Yes | Glucagon-like peptide-2. A real, separate hormone — but not a weight-loss drug. Its approved analog, teduglutide (GATTEX), treats short bowel syndrome [2]. |
| GLP-3 | No | Not a hormone, receptor, or drug. A nickname for retatrutide, which agonizes three receptors: GLP-1, GIP, and glucagon [1]. |
What retatrutide actually is
Retatrutide (Lilly designation LY3437943) is a 39-amino-acid single peptide engineered from a GIP backbone, with a fatty di-acid chain attached so it binds albumin and lasts long enough for weekly dosing [1]. It is described in the peer-reviewed literature as “the first GLP-1/GIP/GCG triple agonist to complete phase 2 trials, with phase 3 studies ongoing” [1]. GCG is glucagon.
- GLP-1 receptor — the appetite and satiety arm, the same one semaglutide works through.
- GIP receptor — the second arm tirzepatide added on top of GLP-1.
- Glucagon receptor — the third arm, unique to retatrutide in this class. It raises energy expenditure and reduces liver fat, and it is the reason the effect size is larger than tirzepatide's.
So “triple” is accurate and “GLP-3” is not: two of the three receptors it hits are not GLP receptors at all. For the trial data behind it, see our retatrutide triple agonist evidence review, and for how it compares head-to-head, retatrutide vs tirzepatide.
You cannot get it from a pharmacy
Retatrutide is investigational. As of August 19, 2026 ClinicalTrials.gov listed 32 registered retatrutide studies, with phase 3 work still active [3]. No FDA-approved retatrutide product exists, which means there is no prescription version, no pharmacy price, and no approved dose.
That is the gap the “GLP-3” label fills commercially. Search results for these terms are heavily populated by vendors selling vials described as “GLP-3 peptide,” “GLP-3 R,” or “GLP-3 RT” — the “R” and “RT” being seller shorthand for retatrutide. These are not prescriptions being filled. They are unapproved material sold outside the drug-approval system, frequently labeled “research use only,” and we cover why that boundary matters in our retatrutide regulatory status and sourcing guide.
Why the nickname stuck
It is a useful shorthand and a bad description. “The next one after tirzepatide” is genuinely hard to say quickly, and “GLP-3” sounds like a version number in a product line people already understand. Mainstream outlets have started addressing the term directly rather than using it, and Lilly itself does not market retatrutide under that name. If you are reading a page that uses “GLP-3” as though it were a drug class rather than a nickname, that is a reasonable signal to check what else on the page is imprecise.
Frequently Asked Questions
References
- 1.Goldney J, Hamza M, Surti F, Davies MJ, Papamargaritis D. Triple Agonism Based Therapies for Obesity. Curr Cardiovasc Risk Rep. 2025. PMID: 40741227.
- 2.Takeda Pharmaceuticals America, Inc. GATTEX (teduglutide) for injection — US Prescribing Information. Describes teduglutide as a 33 amino acid glucagon-like peptide-2 (GLP-2) analog, indicated for short bowel syndrome. FDA DailyMed. 2024. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=66b69c1e-b25c-44d3-b5ff-1c1de9a516fa
- 3.US National Library of Medicine. ClinicalTrials.gov registry — retatrutide (LY3437943) interventional studies, including active phase 3 trials. ClinicalTrials.gov. 2026. https://clinicaltrials.gov/search?intr=retatrutide
Related research
Retatrutide Approval & Access Timeline: TRIUMPH Results, 2027 FDA Filing, No Compounding
Retatrutide is not FDA-approved. Lilly plans to file in the first quarter of 2027, so it will not be prescribable in 2026. TRIUMPH-1 showed up to 25.0% weight loss at 80 weeks, and it cannot legally be compounded under 503A or 503B.
12 min read
Retatrutide Before and After: What TRIUMPH-1 Actually Showed
TRIUMPH-1 (n=2,339; NEJM 2026) reported -25.0% mean weight loss at 80 weeks on retatrutide 12 mg (intention-to-treat; Lilly's press release cited -28.3% on-treatment). Honest framing of transformation magnitude, dose-response, and real-world expectations.
12 min read
Retatrutide Side Effects: Comprehensive Phase 3 Evidence Review
TRIUMPH-1 pivotal phase 3 retatrutide adverse-event review: GI rates, a dysesthesia signal (12.5% vs 0.9% placebo) also seen with high-dose semaglutide, 11.3% discontinuation, and head-to-head AE comparison with Wegovy, Zepbound, and Foundayo.
15 min read
Retatrutide: What We Know About Lilly's Triple Agonist as TRIUMPH-4 Reads Out
Retatrutide is Lilly's investigational triple agonist of the GLP-1, GIP, and glucagon receptors. TRIUMPH-4 showed 28.7% mean weight loss at the highest dose in adults with obesity and knee osteoarthritis. Phase 3 also flagged a dysesthesia signal on the 12 mg dose.
13 min read
Retatrutide TRIUMPH Phase 3: Latest Pipeline Update
In the TRIUMPH-1 phase 3 trial, Lilly's retatrutide produced up to 25.0% weight loss at 80 weeks, and 18.8% in people with type 2 diabetes in TRIUMPH-2. Lilly plans to file with the FDA in Q1 2027. Open safety questions and the access timeline are covered.
11 min read
Retatrutide vs Wegovy: cross-trial weight-loss + safety evidence (2026)
Retatrutide (investigational) -25.0% TBWL at 12 mg / 80 wk in TRIUMPH-1 vs Wegovy (FDA-approved 2021) -14.9% at 68 wk in STEP-1, about 1.7x on a cross-trial basis. No head-to-head RCT. Wegovy has SELECT (20% MACE reduction); retatrutide's outcomes trial is ongoing.
12 min read
Where to get GLP-1 safely: vetted online providers
Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.
No insurance needed · vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
Collective
The lowest flat medication price if you can absorb an annual membership fee
Read full review →Pricing Compare
Get started →CoreAge Rx
Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose
Read full review →Pricing Compare
Get started →Pricing Compare
Get started →